Livzon/Kanova’s Lecankitug Gets China Approval After Beating Secukinumab in Phase 3 Psoriasis Trial
China’s National Medical Products Administration (NMPA) has approved lecankitug (LZM012/XKH004), an IL-17A/IL-17F-targeting monoclonal antibody jointly developed by Livzon Pharmaceutical Group and Beijing Kanova Biopharmaceutical, for the treatment of…
Haisco Strikes $1.5 Billion NewCo Deal with Sentivera for Type 2 Inflammation Asset
Chinese drugmaker Haisco Pharmaceutical Group has struck another billion-dollar cross-border transaction, licensing ex-Greater China rights to a preclinical immunology asset to newly formed U.S. biotech Sentivera in a deal potentially worth more than…
Aiming at an ‘Undruggable” target, Pyrotech’s class 1 small-molecule candidate gets approved for sepsis clinical trials
On August 4, Pyrotech Therapeutics (“Pyrotech”) announced that its independently developed small-molecule pyroptosis inhibitor, PTT-121, has been approved for clinical trials in China, intended for the treatment of sepsis and septic shock.…